This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/projekt/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n5http://linked.opendata.cz/ontology/domain/vavai/
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F01%3A00003665%21RIV12-MSM-11120___/
n7http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F01%3A00003665%21RIV12-MSM-11120___
rdf:type
n5:Vysledek skos:Concept
dcterms:description
The antitumour activity of four N-6-substituted PMEDAP derivatives, Me2NEt-PMEDAP, allyl-PMEDAP, Me-2-PMEDAP and cypr-PMEDAP, selected on the basis of their in vitro cytostatic activity, was studied in an in vivo model of haematological malignancy of inbred Sprague-Dawley rats. These compounds are believed to serve as the prodrugs of another (phosphonomethoxy) ethyl derivative, PMEG (9-[2-phosphonomethoxy) ethyl] guanine. We compared their toxicity and ability to inhibit tumour development in two different dosage regimes with those of their parent compound PMEDAP, as well with PMEG. The study confirmed the anticancer efficacy of the parental compound PMEDAP. Unlike PMEDAP, its N-6-mono- and disubstituted congeners Me2NEt-PMEDAP, allyl-PMEDAP and Me-2-PMEDAP were less potent or exhibited the same antineoplastic effect as PMEDAP. cypr-PMEDAP significantly decreased the survival of lymphoma-bearing rats due to high toxicity, which was approximately the same as that of PMEG, Therefore, these acyclic nucle The antitumour activity of four N-6-substituted PMEDAP derivatives, Me2NEt-PMEDAP, allyl-PMEDAP, Me-2-PMEDAP and cypr-PMEDAP, selected on the basis of their in vitro cytostatic activity, was studied in an in vivo model of haematological malignancy of inbred Sprague-Dawley rats. These compounds are believed to serve as the prodrugs of another (phosphonomethoxy) ethyl derivative, PMEG (9-[2-phosphonomethoxy) ethyl] guanine. We compared their toxicity and ability to inhibit tumour development in two different dosage regimes with those of their parent compound PMEDAP, as well with PMEG. The study confirmed the anticancer efficacy of the parental compound PMEDAP. Unlike PMEDAP, its N-6-mono- and disubstituted congeners Me2NEt-PMEDAP, allyl-PMEDAP and Me-2-PMEDAP were less potent or exhibited the same antineoplastic effect as PMEDAP. cypr-PMEDAP significantly decreased the survival of lymphoma-bearing rats due to high toxicity, which was approximately the same as that of PMEG, Therefore, these acyclic nucle
dcterms:title
Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma
skos:prefLabel
Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma
skos:notation
RIV/00216208:11120/01:00003665!RIV12-MSM-11120___
n3:aktivita
n14:Z n14:P
n3:aktivity
P(GV203/96/K128), P(NL5423), Z(AV0Z4055905), Z(AV0Z5039906), Z(MSM 111200002)
n3:cisloPeriodika
3B
n3:dodaniDat
n11:2012
n3:domaciTvurceVysledku
n9:7449186
n3:druhVysledku
n17:J
n3:duvernostUdaju
n13:S
n3:entitaPredkladatele
n19:predkladatel
n3:idSjednocenehoVysledku
673535
n3:idVysledku
RIV/00216208:11120/01:00003665
n3:jazykVysledku
n4:eng
n3:klicovaSlova
rat; spontaneous lymphoma; PMEDAP derivatives
n3:klicoveSlovo
n10:rat n10:spontaneous%20lymphoma n10:PMEDAP%20derivatives
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[2938ACEC1014]
n3:nazevZdroje
Anticancer Research
n3:obor
n12:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
5
n3:projekt
n16:GV203%2F96%2FK128 n16:NL5423
n3:rokUplatneniVysledku
n11:2001
n3:svazekPeriodika
21
n3:tvurceVysledku
Mandys, Václav Valeriánová, M.
n3:wos
000170276600054
n3:zamer
n7:AV0Z5039906 n7:AV0Z4055905 n7:MSM%20111200002
s:issn
0250-7005
s:numberOfPages
8
n18:organizacniJednotka
11120